203. 22q11.2 deletion syndrome
3 clinical trials,   3 drugs   (DrugBank: 0 drug)   0 gene,   0 pathway

Searched query = "22q11.2 deletion syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04639960
(ClinicalTrials.gov)
September 29, 20173/11/2020Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion SyndromeEffects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome22q11.2 Deletion SyndromeDrug: Risperdal;Drug: PlaceboUniversity of Geneva, SwitzerlandNULLRecruiting11 Years25 YearsAll30N/ASwitzerland
2NCT02895906
(ClinicalTrials.gov)
November 28, 201629/8/2016Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric ConditionsA 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)22q11.2 Deletion SyndromeDrug: NFC-1Aevi Genomic MedicineNULLCompleted12 Years17 YearsAll2Phase 1United States
3NCT04647500
(ClinicalTrials.gov)
August 26, 20163/11/2020Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion SyndromeEffects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome22q11.2 Deletion SyndromeDrug: ConcertaUniversity of Geneva, SwitzerlandNULLRecruiting8 Years25 YearsAll30N/ASwitzerland